AMAG Pharmaceuticals Top Insiders
AMAG Pharmaceuticals employs about 440 people. The company is managed by 40 executives with a total tenure of roughly 339 years, averaging almost 8.0 years of service per executive, having 11.0 employees per reported executive. Examination of AMAG Pharmaceuticals' management performance can provide insight into the company performance.
William Heiden CEO CEO and Director |
Gino Santini Chairman Chairman of the Board |
AMAG |
AMAG Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (3.06) % which means that it has lost $3.06 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (62.88) %, meaning that it created substantial loss on money invested by shareholders. AMAG Pharmaceuticals' management efficiency ratios could be used to measure how well AMAG Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.AMAG Pharmaceuticals Workforce Comparison
AMAG Pharmaceuticals is number one stock in number of employees category among related companies. The total workforce of Biotechnology industry is presently estimated at about 50,181. AMAG Pharmaceuticals maintains roughly 440 in number of employees contributing less than 1% to stocks in Biotechnology industry.
The company has Profit Margin (PM) of (77.18) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (13.88) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $13.88. AMAG Pharmaceuticals Notable Stakeholders
An AMAG Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as AMAG Pharmaceuticals often face trade-offs trying to please all of them. AMAG Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting AMAG Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
William Heiden | CEO and Director | Profile | |
Gino Santini | Chairman of the Board | Profile | |
Alan Butcher | Executive Vice President and Chief Business Officer | Profile | |
Oscar Sanchez | Vice President - Quality | Profile | |
Julie Krop | Chief Medical Officer and Senior Vice President - Clinical Development and Regulatory Affairs | Profile | |
Todd Horn | General Manager - CBR and Senior Vice President - Consumer Marketing & Sales at AMAG | Profile | |
Laura Williams | Senior Vice President - Clinical Development | Profile | |
Arpad Simon | Vice President - Pharmacovigilance | Profile | |
Kathryn Payne | Vice President - External Affairs. | Profile | |
Scott McMillan | Senior Vice President - Quality and Technical Operations | Profile | |
Joseph Vittiglio | Senior Vice President General Counsel, Secretary | Profile | |
Nancy Griffith | Vice President - Scientific Communications And Medical Operations | Profile | |
Paul Williams | Senior Vice President - Sales and Marketing, Lumara Health and Cord Blood Registry | Profile | |
Mark Stanton | Vice President - Market Access and Corporate Accounts | Profile | |
Edward Myles | CFO, Senior Vice President - Finance, Treasurer | Profile | |
Nicholas Grund | Executive Vice President Chief Commercial Officer | Profile | |
Aaron Pelta | Vice President - Business Development | Profile | |
Elizabeth Bolgiano | Senior Vice President of Human Resources | Profile | |
Tony Casciano | Senior Vice President of Sales and Marketing - Hematology and Oncology business | Profile | |
Robert Brenner | Senior Vice President - Medical Affairs | Profile | |
Helen Milton | Vice President - Regulatory Affairs | Profile | |
Frank Thomas | Pres and COO | Profile | |
Nathan McBride | CIO and Sr. VP of Innovation Architects | Profile | |
Edward Jordan | Sr. VP of Sales and Marketing | Profile | |
Melissa Klug | Sr. VP of Bus. Devel. and Strategy | Profile | |
Cooper Russell | Independent Director | Profile | |
Kathrine OBrien | Independent Director | Profile | |
Davey Scoon | Independent Director | Profile | |
John Fallon | Director | Profile | |
Anne Phillips | Independent Director | Profile | |
Robert Perez | Independent Director | Profile | |
Katie Payne | Executive Director, Investor Relations & Corporate Communications | Profile | |
James Sulat | Independent Director | Profile | |
Lesley Cooper | Independent Director | Profile | |
Brian Kelley | Independent Director | Profile | |
Barbara Deptula | Independent Director | Profile | |
Lesley Russell | Independent Director | Profile | |
Linda Lennox | VP of Investor Relations and Corporate Communications | Profile | |
Tracy Berns | Chief Compliance Officer | Profile | |
Anthony Casciano | Chief Commercial Officer | Profile |
AMAG Pharmaceuticals Workforce Analysis
Traditionally, organizations such as AMAG Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare AMAG Pharmaceuticals within its industry.AMAG Pharmaceuticals Manpower Efficiency
Return on AMAG Pharmaceuticals Manpower
Revenue Per Employee | 682.1K | |
Revenue Per Executive | 7.5M | |
Net Loss Per Employee | 526.4K | |
Net Loss Per Executive | 5.8M | |
Working Capital Per Employee | 819.9K | |
Working Capital Per Executive | 9M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the AMAG Pharmaceuticals information on this page should be used as a complementary analysis to other AMAG Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Consideration for investing in AMAG Stock
If you are still planning to invest in AMAG Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AMAG Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |